Over 1,600 attendees from 33 countries are gathering in downtown Oakland to demonstrate the successes, the strength, and the spirit of the new wave of psychedelic science and medicine. By Brad Burge | Communications Director, MAPS Psychedelic Science 2013 starts tomorrow. It is a genuinely historic moment. At Psychedelic Science 2013, over 100 of the [...]
Apr 18 2013 | Posted in
411 Contributors,
Addiction,
AIDS HIV,
Alzheimer's,
Amyotrophic Lateral Sclerosis (Lou Gehrig's),
Anorexia,
Anti-inflammatory,
Anxiety,
Appetite,
Arizona,
Attention Deficit Hyperactivity Disorder (ADD),
Brad Burge,
Brain trauma,
California,
Canada,
Cancer,
Cannabis Science,
Colorado,
Countries Outside of the US,
Crohn's Disease,
Czech Republic,
Endogenous Cannabinoid Signaling System (eCBss),
Epilepsy,
Featured,
Germany,
Glaucoma,
Harm Reduction,
Holland,
Israel,
Latest Headlines,
Massachusetts,
Media,
Medical 411,
Migraines,
Multidisciplinary Association of Psychedelic Studies (MAPS),
Nausea,
Neuropathy,
Organizations,
Pain Management,
Parkinson's Disease,
Patient Stories,
Physician Story,
Post Traumatic Stress Disorder,
Rheumatoid Arthritis,
States and Laws,
Switzerland,
U.S. Government,
Washington,
Washington DC,
Wasting Syndrome |
Read More »
By Matt Sledge | Published in The Huffington Post The Maryland House of Delegates approved a bill that would make medical marijuana legally available through academic medical research centers in a 108-28 vote on Monday. The bill will now head to the state Senate, where supporters expect passage. Maryland’s marijuana bill is limited, compared to [...]
Mar 29 2013 | Posted in
AIDS HIV,
Anti-inflammatory,
Anxiety,
Brain trauma,
Cancer,
Crohn's Disease,
Epilepsy,
Featured,
Latest Headlines,
Marijuana Policy Project (MPP),
Maryland,
Medical 411,
Organizations,
Post Traumatic Stress Disorder,
States and Laws |
Read More »
By Sunil Aggarwal | Published by Americans for Safe Access I am honored and delighted to be able to publish here a new comprehensive piece written by Dr. Lester Grinspoon, Emeritus Professor of Psychiatry at Harvard Medical School, entitled “Cannabinopathic Medicine”. Dr. Grinspoon started writing this piece in 2012, when I was privileged to read [...]
Mar 28 2013 | Posted in
411 Contributors,
Addiction,
AIDS HIV,
Alzheimer's,
Americans for Safe Access,
Anandamide,
Anti-inflammatory,
Anxiety,
Appetite,
Attention Deficit Hyperactivity Disorder (ADD),
Autism,
Brain trauma,
Breaking News,
Cancer,
Cannabinoid Receptors,
Cannabinopathic,
Cannabis Science,
Countries Outside of the US,
Crohn's Disease,
Depression,
Endogenous Cannabinoid Signaling System (eCBss),
Epilepsy,
Featured,
Glaucoma,
Holland,
Immune System,
India,
Israel,
Latest Headlines,
Medical 411,
memory,
Migraines,
Multiple Sclerosis,
Nail Patella Syndrome,
Nausea,
Neuropathy,
Organizations,
Pain Management,
Parkinson's Disease,
Physician Story,
Post Traumatic Stress Disorder,
Psoriasis,
Rheumatoid Arthritis,
Seizures,
Stress,
Sunil Aggarwal,
Wasting Syndrome |
Read More »
Medical marijuana is now legal in 18 states, but it’s clear we’ve discovered a fraction of its potential for health By Allan Badiner | Published in AlterNet.org There are now legal medical cannabis programs in 18 states plus Washington, DC, with pot fully legal for adults in two other states. Ironically, however, the actual healing [...]
Dec 14 2012 | Posted in
AIDS HIV,
Anorexia,
Anti-inflammatory,
Anxiety,
Appetite,
Arizona,
Autism,
Brain trauma,
California,
Cancer,
Colorado,
Countries Outside of the US,
Crohn's Disease,
Epilepsy,
Featured,
Glaucoma,
Harm Reduction,
India,
Insomnia,
Latest Headlines,
Lupus,
Media,
Medical 411,
Migraines,
Multiple Sclerosis,
Nail Patella Syndrome,
Neuropathy,
Organizations,
Pain Management,
Parkinson's Disease,
Photo Gallery,
Post Traumatic Stress Disorder,
Project CBD,
Rheumatoid Arthritis,
Seizures,
Spain,
States and Laws,
Stress,
Video,
Washington,
Washington DC,
Wasting Syndrome |
Read More »
A 6-year-old boy with epilepsy has been suffering fewer seizures since taking medical marijuana. By Kyung Lah | Published by CNN The video with this story is hard to watch. In it, Jayden is having an epileptic seizure. His father, Jason David, explains what it’s like to hold his son when he’s screaming. “I would [...]
Dec 7 2012 | Posted in
AIDS HIV,
Attention Deficit Hyperactivity Disorder (ADD),
Autism,
Brain trauma,
Breaking News,
Cancer,
Cannabinoids,
Cannabis Science,
Endogenous Cannabinoid Signaling System (eCBss),
Epilepsy,
Featured,
Latest Headlines,
Media,
Medical 411,
Seizures,
Video |
Read More »
In our third segment of the International Association of Cannabinoid Medicine’s 2011 Cannabinoid Conference in Europe, Naturopathic Doctor Michelle Sexton discusses the Endogenous Cannabinoid System from the perspective of pain management, inflammation, and toxicity, and how dis-ease may be modified by the use of Phytocannabinoids. By Dr. Michelle Sexton | September 26, 2011 IACM Program: [...]
Sep 26 2011 | Posted in
411 Contributors,
AIDS HIV,
Alzheimer's,
Amyotrophic Lateral Sclerosis (Lou Gehrig's),
Anti-inflammatory,
Brain trauma,
Cannabidiol,
Cannabinoid Receptors,
Cannabinoids,
Cannabis Science,
Countries Outside of the US,
Depression,
Dr. Michelle Sexton ND,
Endogenous Cannabinoid Signaling System (eCBss),
Epilepsy,
Featured,
Germany,
Huntington's Disease,
Inflammation,
International Association for Cannabinoid Medicines,
Latest Headlines,
Media,
Medical 411,
Migraines,
Multiple Sclerosis,
Neuropathy,
Organizations,
Pain Management,
Parkinson's Disease,
Photo Gallery,
Stroke |
Read More »
Cannabis plants are being grown at a secret facility in the south of England in the hope of producing a new treatment for epilepsy. By Richard Gray | Published in The Telegraph Researchers at the University of Reading have discovered that three compounds found in cannabis leaves can help to reduce and control seizures in [...]
Apr 11 2011 | Posted in
Cannabis Science,
Countries Outside of the US,
Epilepsy,
Featured,
Medical 411,
Multiple Sclerosis,
Organizations,
Pain Management,
Patients Out of Time,
Seizures,
United Kingdom |
Read More »
By Kandice Hawes | OC NORML Chapter President Roughly ten thousand people are becoming Senior Citizens everyday for the next 19 years, according to USA Today magazine. In response to this growing population and the need for education about alternative medical solutions, the Apothecary Senior Citizens Project was started. The purpose of the project was [...]
Apr 11 2011 | Posted in
Alzheimer's,
Appetite,
Breaking News,
California,
Cancer,
Cannabis Science,
Depression,
Diabetes,
Dispensaries & Collectives,
Epilepsy,
Featured,
Latest Headlines,
Medical 411,
Neuropathy,
Organizations,
Osteoporosis,
Pain Management,
Patient Stories,
Physician Story,
Rheumatoid Arthritis,
States and Laws,
Uncategorized |
Read More »
We have recently shown that the phytocannabinoid cannabidiol (CBD) reduces seizure severity and lethality in the well-established in vivo model of pentylenetetrazole-induced generalised seizures, suggesting that earlier, small-scale clinical trials examining CBD effects in epileptic subjects warrant renewed attention.
Here, we report the effects of pure CBD (1, 10 and 100mg/kg) in two other established rodent seizure models, the acute pilocarpine model of temporal lobe seizure and the penicillin model of partial seizure. Seizure activity was video recorded and scored offline using model-specific seizure severity scales. CBD (all doses) significantly reduced the percentage of animals experiencing the most severe pilocarpine-induced seizures.
When Valerie Curran asked college students to put her in touch with their doobie-smoking friends, she was being serious. Curran is neither a drug dealer nor abuser, but she does tote a license to carry marijuana. She is a scientist at University College London, where she’s studying the impact of drugs on memory. Her most recent research explored marijuana use in a naturalistic setting: college-aged kids, in their own homes, smoking from their own stashes. That may sound controversial, but Curran has a pragmatic outlook on illegal drug use: “Cannabis is the world’s most popular illegal substance,” she said. “If people are going to use it, they should be safe and we should know the possible impacts.”
